Five Prime Therapeutics, Inc. (FPRX) Position Decreased by UBS Asset Management Americas Inc.

UBS Asset Management Americas Inc. reduced its holdings in shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by 16.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 102,090 shares of the biotechnology company’s stock after selling 20,130 shares during the quarter. UBS Asset Management Americas Inc. owned 0.37% of Five Prime Therapeutics worth $3,074,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in FPRX. Creative Planning raised its position in Five Prime Therapeutics by 0.8% in the second quarter. Creative Planning now owns 6,744 shares of the biotechnology company’s stock valued at $203,000 after purchasing an additional 54 shares during the last quarter. Laurion Capital Management LP bought a new position in Five Prime Therapeutics in the first quarter valued at about $210,000. Rockefeller Financial Services Inc. bought a new position in Five Prime Therapeutics in the second quarter valued at about $210,000. BlueCrest Capital Management Ltd bought a new position in Five Prime Therapeutics in the first quarter valued at about $254,000. Finally, Legal & General Group Plc raised its position in Five Prime Therapeutics by 3.1% in the second quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 287 shares during the last quarter. Institutional investors and hedge funds own 84.05% of the company’s stock.

Shares of Five Prime Therapeutics, Inc. (FPRX) opened at 43.52 on Friday. Five Prime Therapeutics, Inc. has a 52 week low of $25.97 and a 52 week high of $60.98. The firm’s market cap is $1.22 billion. The stock has a 50 day moving average price of $35.97 and a 200 day moving average price of $32.00.

Five Prime Therapeutics (NASDAQ:FPRX) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.43). Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The company had revenue of $7.80 million during the quarter, compared to the consensus estimate of $8.32 million. During the same period last year, the firm posted ($0.49) EPS. The company’s revenue was down 16.1% on a year-over-year basis. Equities analysts expect that Five Prime Therapeutics, Inc. will post ($5.29) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Five Prime Therapeutics, Inc. (FPRX) Position Decreased by UBS Asset Management Americas Inc.” was reported by Stock Observer and is owned by of Stock Observer. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.thestockobserver.com/2017/10/13/five-prime-therapeutics-inc-fprx-position-decreased-by-ubs-asset-management-americas-inc.html.

In other Five Prime Therapeutics news, Director William R. Ringo sold 1,800 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $40.26, for a total transaction of $72,468.00. Following the completion of the transaction, the director now owns 1,200 shares of the company’s stock, valued at approximately $48,312. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William R. Ringo sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $38.00, for a total value of $76,000.00. Following the transaction, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $76,000. The disclosure for this sale can be found here. Insiders own 6.50% of the company’s stock.

Several equities analysts have commented on the company. Jefferies Group LLC reiterated a “buy” rating and issued a $52.00 target price (down from $55.00) on shares of Five Prime Therapeutics in a research report on Thursday, August 10th. Zacks Investment Research downgraded Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. BidaskClub downgraded Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. BMO Capital Markets reiterated a “hold” rating and issued a $39.00 target price on shares of Five Prime Therapeutics in a research report on Friday, September 22nd. Finally, ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. Five Prime Therapeutics currently has an average rating of “Hold” and an average price target of $57.50.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply